Changes in Patient Functioning and Disability: Results from Two Phase 3 Double-Blind Placebo-Controlled Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2)

被引：0
|
作者：
Ford, J. [1 ]
Ayer, D. [1 ]
Zhang, Q. [2 ]
Carter, J. [2 ]
Skljarevski, V [2 ]
Aurora, S. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
HEADACHE | 2018年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PS37
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [41] Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert
    NEUROLOGY, 2020, 94 (15)
  • [42] Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    NEUROLOGY, 2021, 96 (15)
  • [43] IMPACT OF FREMANEZUMAB ON DISABILITY SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE: POOLED RESULTS OF 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDIES
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    CEPHALALGIA, 2020, 40 : 93 - 94
  • [44] Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
    Sun, Hong
    Dodick, David W.
    Silberstein, Stephen
    Goadsby, Peter J.
    Reuter, Uwe
    Ashina, Messoud
    Saper, Joel
    Cady, Roger
    Chon, Yun
    Dietrich, Julie
    Lenz, Robert
    LANCET NEUROLOGY, 2016, 15 (04): : 382 - 390
  • [45] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, H. C.
    Wang, S.
    Skljarevski, V
    Ahl, J.
    Millen, B.
    Aurora, S. K.
    Yang, J.
    HEADACHE, 2017, 57 (08): : 1336 - 1337
  • [46] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    CEPHALALGIA, 2017, 37 : 338 - 338
  • [47] A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [48] A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase
    Bardos, Jennifer N.
    Goadsby, Peter J.
    Dodick, David
    Leone, Massimo
    Oakes, Tina M.
    Martinez, James M.
    Millen, Brian A.
    Zhou, Chunmei
    Dowsett, Sherie A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    Conley, Robert
    NEUROLOGY, 2019, 92 (15)
  • [49] Changes in Work Productivity and Interictal Burden: Results from a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Galcanezumab in Adults with Treatment-Resistant Migraine (CONQUER)
    Garcia-Azorin, D.
    Ford, J.
    Buse, D.
    Hand, A.
    Wietecha, L.
    Detke, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 160 - 160
  • [50] Changes in Work Productivity and Interictal Burden: Results from a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Galcanezumab in Adults with Treatment-Resistant Migraine (CONQUER)
    Garcia-Azorin, David
    Ford, Janet
    Buse, Dawn
    Hand, Austin
    Wietecha, Linda
    Detke, Holland
    NEUROLOGY, 2020, 94 (15)
12345